CLAIMS

1. Use of a composition comprising allogeneic cytotoxic T cells (CTLs) expressing a T cell receptor that specifically binds to an EBV peptide presented on a class I MHC in the manufacture of a medicament for treating or preventing an EBV-associated autoimmune disease in a subject.

2. The use of claim 1, wherein said CTLs were obtained by selecting from a cell bank allogeneic CTLs expressing a T cell receptor that specifically binds to an EBV peptide presented on a class I MHC.

3. The use of claim 1 or 2, wherein said CTLs were prepared by incubating a sample comprising allogeneic CTLs with antigen-presenting cells (APCs) presenting an EBV peptide, thereby inducing proliferation of peptide-specific CTLs expressing a T cell receptor that specifically binds to an EBV peptide presented on a class I MHC.

4. The use of any one of claims 1 to 3, wherein said CTLs were prepared by :

a) incubating APCs with a nucleic acid construct encoding for an EBV peptide, thereby inducing the APCs to present an EBV peptide; and

b) inducing peptide-specific CTL proliferation by incubating a sample comprising allogeneic CTLs with the EBV peptide-presenting APCs, thereby inducing the proliferation of CTLs expressing a T cell receptor that specifically binds to an EBV peptide presented on a class I MHC.

5. The use of any one of claims 1 to 4, wherein the class I MHC is encoded by an HLA allele that is present in the subject.

6. The use of claim 4 or 5, wherein the nucleic acid construct is a viral vector.

7. The use of claim 6, wherein the viral vector is AdE1-LMPpoly.

8. The use of any one of claims 1 to 7, wherein the allogeneic CTLs are stored in a cell bank before being administered to the subject.

9. The use of any one of claims 1 to 8, wherein the EBV-associated autoimmune disease is multiple sclerosis (MS).

10. The use of any one of claims 1 to 9, wherein the EBV-associated autoimmune disease is primary progressive MS (PPMS), secondary progressive MS (SPMS), or relapsing remitting MS (RRMS).

11. The use of any one of claims 1 to 8, wherein the EBV-associated autoimmune disease is rheumatoid arthritis (RA).

12. The use of any one of claims 3 to 11, wherein the sample comprising CTLs is incubated with one or more cytokines.

13. The use of any one of claims 3 to 12, wherein the APCs comprise B cells.

14. The use of any one of claims 3 to 12, wherein the APCs comprise antigen-presenting T-cells.

15. The use of any one of claims 3 to 12, wherein the APCs comprise dendritic cells.

16. The use of any one of claims 3 to 12, wherein the APCs comprise artificial antigen-presenting cells.

17. The use of claim 16, wherein the artificial antigen-presenting cells are aK562 cells.

18. The use of any one of claims 3 to 17, wherein the sample comprises peripheral blood mononuclear cells (PBMCs).

19. The use of any one of claims 1 to 18, wherein the EBV peptide comprises a LMP1 peptide or fragment thereof.

20. The use of any one of claims 1 to 18, wherein the EBV peptide comprises a LMP2A peptide or fragment thereof.

21. The use of any one of claims 1 to 18, wherein the EBV peptide comprises an EBNA1 peptide or fragment thereof.